Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2026-03-07 @ 10:44 PM
Study NCT ID:
NCT02805660
Status:
TERMINATED
Last Update Posted:
2021-04-06
First Post:
2016-06-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC
Sponsor:
Mirati Therapeutics Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | MGCD0103 | View |
| None | MEDI4736 | View |
| None | Mocetinostat | View |
| None | Durvalumab | View |
| None | HDAC Inhibitor | View |
| None | PD-L1 Inhibitor | View |
| None | Phase 1 | View |
| None | Phase 2 | View |
| None | Metastatic Solid Tumor | View |
| None | Non-small cell lung cancer | View |
| None | immunotherapy | View |
| None | checkpoint inhibitor | View |